Clinical trials: Psychiatric Disorder
Substance Withdrawal Syndrome
Effect of Ondansetron for Withdrawal Symptoms
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications.
- Trial name
- NCT00695864
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Stanford University
Treatment Resistant Depression
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
- Trial name
- NCT03680781
- Testing
- Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Depression Mild, Depressive Disorder, Major
Cognitive Fitness for Depression in Older Adults
This research is being done to determine if computerized administered cognitive fitness activities will improve thinking and depression in older depressed adults who are being treated with antidepressants.
- Conditions
- Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
- Trial name
- NCT04790630
- Testing
- Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- UConn Health
Delirium, Cognitive Decline
Early Cognitive Intervention in Delirium
This is a randomized control trial to determine if early cognitive training and rehabilitation improve 4-month cognition in hospitalized older (>=65 years old) delirious patients with and without Alzheimer's disease and related…
- Conditions
- Delirium, Cognitive Decline, Dementia
- Trial name
- ECID (NCT04740567)
- Testing
- Cognitive Training, Goal Management Training
- Where
- 2 sites in United States
- Volunteers
- 283 people
- Sponsor
- Vanderbilt University Medical Center
Opioid Use Disorder, HIV Infections
Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington
The investigators will implement a non-randomized observational clinical trial that will include a pop-up clinic for women who inject drugs (WWID) near venues for exchange sex and drug use in north Seattle.
- Conditions
- Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea
- Trial name
- NCT06187064
- Testing
- Mobile Van Clinic
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Washington
Endometriosis, Central Sensitisation
Dyspareunia and Central Sensitization
Background: Endometriosis affects 10% of reproductive aged females, and can have a negative impact on sexual quality of life. Endometriosis can cause pelvic pain with deep penetration during intercourse, as well as other sexual…
- Conditions
- Endometriosis, Central Sensitisation, Dyspareunia
- Trial name
- NCT03216330
- Testing
- No Intervention
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- BC Women's Hospital & Health Centre
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant
Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)
In this pilot study, we propose to test whether high frequency stimulation of the subcallosal cingulate (SCC) is a safe and efficacious antidepressant treatment in five TRD patients, to compare the effects of left-sided vs.
- Conditions
- Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
- Trial name
- NCT01898429
- Testing
- SCC DBS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Paul Holtzheimer
Bedwetting, Nocturnal Enuresis
Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm
Identify the dry night rate in patients using the GoGoband® nocturnal enuresis device vs a standard Pflaundler bedwetting alarm.
- Conditions
- Bedwetting, Nocturnal Enuresis, Urinary Incontinence
- Trial name
- NCT05214131
- Testing
- gogoband, SNEA group
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yale University
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD.
- Trial name
- NCT00768430
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Baylor College of Medicine
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Autism Spectrum Disorder, Anxiety
Specifying and Treating Anxiety in Autism Research
In the Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder (STAAR) study, we conducted a16-week randomized comparative treatment trial of the Behavioral Intervention for Anxiety in Children with Autism…
- Trial name
- STAAR (NCT03279471)
- Testing
- Sertraline, CBT/BIACA
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Davis
Alcohol Dependence
Pharmacogenetic Response to Naltrexone For Alcohol Dependence
The aims of the study are to test for treatment outcome differences in alcohol dependent subjects randomly assigned to 12 weeks of treatment with NTX (50mg/day) or placebo among those with one or two copies of the Asp40 allele of…
- Trial name
- NCT00831272
- Testing
- naltrexone
- Where
- 4 sites in United States
- Volunteers
- 221 people
- Sponsor
- David Oslin
Schizophrenia
A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
The primary objective of this study is to investigate whether a single infusion of intravenous sodium nitroprusside (0.5 μg/kg/min for 4 hours) is superior to placebo (5% dextrose solution) at in treating positive and negative…
- Trial name
- NCT02164981
- Testing
- sodium nitroprusside
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Narcolepsy
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
The purpose of this study was to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1).
- Trial name
- NCT06179407
- Testing
- MK-6552
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Psychosis, Substance Abuse
Effect Evaluation of Individual Placement and Support (IPS)
Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to…
- Conditions
- Psychosis, Substance Abuse, Depression, Anxiety
- Trial name
- NCT01964092
- Testing
- Individual Placement and Support, Ordinary employment schemes
- Where
- Norway
- Volunteers
- 410 people
- Sponsor
- NORCE Norwegian Research Centre AS
Alzheimer's Disease, Dementia
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
This study will evaluate acute symptomatic improvements in cognitive performance in healthy elderly participants with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00874939
- Testing
- MK-0249 7.5 mg, MK-0249 25 mg, Donepezil 5mg
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
REM Behavior Disorder, Parkinsonism
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Parkinson's disease (PD) is the second most common neurodegenerative disorder of the elderly that affects a million patients in US. Sleep dysfunction impacts up to 90% of PD patients.
- Trial name
- NCT00745030
- Testing
- Rozerem
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
PTSD
Pilot Trial of Mobile Mantram Delivery
Mantram Repetition Program (MRP) is a meditation practice that involves silent repetition of a spiritual word, one-pointed attention, and slowing down. It has been shown to help reduce PTSD symptoms among Veterans.
- Trial name
- mMRP (NCT05998967)
- Testing
- Mobile Mantram Repetition Program
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.